×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: MK-1167 Phase 2 AD Trial (MK-1167-008)
clinical
1,373 words
KG: MK-1167 Phase 2 AD Trial (MK-1167-008)
2026-03-25
kind:clinical-trial
section:clinical-trials
state:published
status:phase-2
disease:alzheimers-disease
Contents
MK-1167 Phase 2 AD Trial (MK-1167-008)
Knowledge Graph
Related Hypotheses (26)
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
Cryptic Exon Silencing Restoration
Score: 0.46
Cross-Seeding Prevention Strategy
Score: 0.45
APOE Isoform Conversion Therapy
Score: 0.44
Glycine-Rich Domain Competitive Inhibition
Score: 0.43
Prime Editing Precision Correction of APOE4 to APOE3 in Micr
Score: 0.62
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming
Score: 0.61
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S
Score: 0.60
Microbial Inflammasome Priming Prevention
Score: 0.58
SASP-Mediated Cholinergic Synapse Disruption
Score: 0.56
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Phase-Separated Organelle Targeting
Score: 0.52
Sleep Spindle-Synaptic Plasticity Enhancement
Score: 0.49
Stress Granule Phase Separation Modulators
Score: 0.49
Gut Barrier Permeability-α-Synuclein Axis Modulation
Score: 0.49
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
Metabolic Switch Targeting for A1→A2 Repolarization
Score: 0.48
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
Metabolic Circuit Breaker via Lipid Droplet Modulation
Score: 0.48
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46
Excitatory Neuron Vulnerability via SLC17A7 Downregulation
Score: 0.44
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
Score: 0.42
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.34
Show 21 more
Related Analyses (5)
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Related Experiments (7)
RBG treatment in ApoE-/- atherosclerosis mouse model
validation · proposed · Score: 0.90
Leukocyte gene expression analysis in COVID-19 patients
exploratory · proposed · Score: 0.90
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40
Neural Stem Cell Therapy for Alzheimer's Disease
clinical · proposed · Score: 0.40
NLRP3 Inflammasome Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Sex Differences in Alzheimer's Disease — mechanisms and ther
clinical · proposed · Score: 0.40
Show 2 more
See Also (15)
vitamin-d-therapy-neurodegeneration
therapeutic · Pages share 7 hypotheses
TREM2 Agonist Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
Trace Amine-Associated Receptor (TAAR) Modulator Therap
therapeutic · Pages share 7 hypotheses
SYK Kinase Inhibitor Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
STING Inhibitor Therapy in Neurodegeneration
therapeutic · Pages share 7 hypotheses
Specialized Pro-Resolving Mediator (SPM) Therapy for Ne
therapeutic · Pages share 7 hypotheses
Specialized Pro-Resolving Mediator (SPM) Therapies for
therapeutic · Pages share 7 hypotheses
Somatostatin Receptor Modulator Therapy in Neurodegener
therapeutic · Pages share 7 hypotheses
S100 Protein (S100A8/A9/A12) Modulator Therapy for Neur
therapeutic · Pages share 7 hypotheses
RNA Targeting Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
Progranulin Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
nt-3-therapy-neurodegeneration
therapeutic · Pages share 7 hypotheses
Neurotensin Receptor Modulator Therapy for Neurodegener
therapeutic · Pages share 7 hypotheses
Nanoparticle Drug Delivery for Neurodegeneration
therapeutic · Pages share 7 hypotheses
N-Acetylcysteine Therapy for Neurodegeneration
therapeutic · Pages share 7 hypotheses
Show 10 more
Knowledge Graph (2 edges)
MK-1167 Phase 2 AD Trial (MK-1167-008)
references
APOE
MK-1167 Phase 2 AD Trial (MK-1167-008)
references
NLRP3